Clinical Trial Update: Modulation of Gut Microbiota by Rifaximin in PD Patients [Phase 1, Phase 2]

View source ↗

Summary

Early-phase clinical trial update evaluating rifaximin to modulate gut microbiota in Parkinson's disease patients with inflammatory considerations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammation
• Parkinson Disease

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Taipei Medical University Shuang Ho Hospital | Conditions: Parkinson Disease, Inflammation | Phase 1, Phase 2 | Status: UNKNOWN